A Phase I/IIa trial of NVG-222 in blood cancers

This study is for adults, aged 18 or older, who have been diagnosed with certain types of blood cancer. This includes cancers like some forms of lymphoma and leukaemia. It's important that your cancer cells are likely to have a specific protein called ROR1 on their surface, as the drug NVG-222 targets this.

You would be eligible if your cancer has come back after previous treatments, or if it has stopped responding to standard treatments such as chemotherapy, CAR T-cell therapy, or stem cell transplants. You might also be considered if your doctor believes standard treatments aren't right for you, or if you've chosen not to have them.

There are also some medical checks the team will need to do, like ensuring your general health allows you to take part safely. Your doctor will discuss all the specific criteria with you to see if this study could be an option.

If you decide to take part, the study involves two main stages. In the first stage (Phase I), one person at a time will start with a very low dose of NVG-222. If there are no serious problems, the next person will receive a slightly higher dose, and this continues until the safest dose is found. Then, in the second part of Phase I, small groups of participants will receive different doses, again starting low, to confirm the best and safest dose.

Once the safest dose is known, the study moves to Phase II. Here, a larger number of people with specific types of blood cancer will receive this established dose of NVG-222. This phase helps researchers understand more about how well the drug works against cancer. You will have regular visits for check-ups, blood tests, and scans to monitor your health, side effects, and how the medicine is working. The study is planned to run from June 2025 to October 2030, and your doctor will explain your individual treatment schedule and how long you might be involved.